MARKET COMPOSITE
CCEL - Cryo-Cell International, Inc.7:57:40 PM 4/26/2024
Price
$8.49
+ 0.69 (8.85%)
Cryo-Cell International Inc., founded in 1989, is the world’s first private cord blood bank and is internationally recognized as the industry leader. More than 500,000 parents from 87 countries have entrusted Cryo-Cell International with their baby’s cord blood and cord tissue stem cells. Cryo-Cell’s mission is to provide clients with state-of-the-art cord blood and cord tissue cryopreservation services, and support the advancement of regenerative medicine. Cryo-Cell aims to help more patients significantly improve their lives through the utilization of the unique immunomodulatory and potential regenerative properties found in the cord blood and cord tissue. In February 2021, Cryo-Cell entered into an exclusive, collaborative license agreement with Duke University that grants Cryo-Cell the rights to certain intellectual property, proprietary processes and regulatory/clinical data related to cord blood and cord tissue developed at The Marcus Center for Cellular Cures at Duke University. Cryo-Cell anticipates opening infusion clinics to treat patients with conditions such as autism, cerebral palsy, and traumatic brain injuries under the rights granted to Duke University through the FDA’s Expanded Access Program. In addition to these, the license agreement includes other clinical indications currently being studied, such as adult stroke, multiple sclerosis, osteoarthritis and COVID-19.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Stock news

    OLDSMAR, Fla., April 15, 2024--Cryo-Cell International, Inc. (NYSE American LLC: CCEL ) (the "Company"), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 29, 2024.

    OLDSMAR, Fla., March 25, 2024--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the "Company" or "Cryo-Cell"), the world’s first private cord blood bank to separate and store stem cells in 1992, today announced that its Board of Directors has authorized the spin-off of its newly formed subsidiary, Celle Corp., to the Cryo-Cell shareholders and to explore all strategic alternatives for Cryo-Cell (post spin-off) to maximize shareholder value, including, but not limited to, equity and/or de

    OLDSMAR, Fla., February 28, 2024--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the "Company"), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2023.

    NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Maxim Group LLC, a full-service investment banking, securities and wealth management firm, and M-Vest, a digital community built for issuers, investors, and thought leaders, present the 2024 Healthcare IT Virtual Conference. The conference will take place on Wednesday, January 24th, & Thursday, January 25th, 2024, starting at 9:00 a.m. ET. We will be presenting our 2024 Healthcare IT Virtual Conference. Allen Klee, Senior Research Analyst at Maxim Grou

    OLDSMAR, Fla., October 12, 2023--Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the "Company"), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2023.

    OLDSMAR, Fla., July 14, 2023--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the "Company"), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2023.

    OLDSMAR, Fla., April 21, 2023--Cryo-Cell International, Inc. (NYSE American LLC: CCEL ) (the "Company"), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 28, 2023.

    OLDSMAR, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2022. Financial Results Revenue Consolidated revenues for fiscal 2022 were $30.3 million compared to $28.9 million for fiscal 2021. The revenues for fiscal 2022 consisted of $29.8 million in processing and storage fee revenue, $104,000 i

    NEW YORK, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Maxim Group LLC, a full-service investment banking, securities and wealth management firm, and M-Vest, a digital community built for issuers, investors, and thought leaders, present the Healthcare IT Virtual Conference. The conference will take place on Wednesday, January 25th at 8:15 A.M. ET Maxim Group LLC presents the Healthcare IT Virtual Conference. Participating companies focus on technology addressing rising health care costs, and scarcity of wo

    OLDSMAR, Fla., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2022. Financial Results Revenue Consolidated revenues for the third quarter of fiscal 2022 were $7.7 million compared to $7.5 million for the third quarter of fiscal 2021. The revenues for the third quarter of fiscal 2022 c